List of works - Stephanie L Safgren

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

scientific article published on 18 February 2019

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin

scientific article

A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study

scientific article published on 01 March 2007

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

scientific article published on 01 October 2006

A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma.

scientific article published in September 2000

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

scientific article published on 19 May 2020

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

scientific article

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. ⬇️

scientific article published on 4 December 2012

Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation

scientific article published on 15 September 2020

Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats

scientific article

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials

scientific article published on 31 August 2011

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen

scientific article

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer

scientific article published on 30 August 2017

GLI1/GLI2 functional interplay is required to control Hedgehog/GLI targets gene expression

scientific article published on 07 August 2020

Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression

scientific article published on September 2008

Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial

scientific article

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

scientific article

Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma

scientific article published in 2017

Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines

scientific article published on 28 May 2008

Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language

scientific article

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

scientific article

Pharmacokinetics of dacarbazine (DTIC) in pregnancy

scientific article

Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies

scientific article

Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study

scientific article

Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia

scientific article

Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group

scientific article published on October 2002

Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group

scientific article published on 01 April 2007

Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors

scientific article published on June 2004

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

scientific article published on 01 February 2005

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

scientific article

Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).

scientific article

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study

scientific article

Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM

scientific article

RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis

scientific article published on 18 May 2021

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

scientific article published on 3 October 2011

Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent

scientific article

The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex

scientific article published on 27 January 2020

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

scientific article

The transcription factor GLI1 cooperates with the chromatin remodeler SMARCA2 to regulate chromatin accessibility at distal DNA regulatory elements

scientific article published on 06 May 2020

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

scientific article published on 10 October 2013

Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide.

scientific article published in April 2001

List of works by Stephanie L Safgren

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin

A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma.

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. ⬇️

Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation

Comparative uterotrophic effects of endoxifen and tamoxifen in ovariectomized Sprague-Dawley rats

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer

GLI1/GLI2 functional interplay is required to control Hedgehog/GLI targets gene expression

Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression

Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma

Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines

Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

Pharmacokinetics of dacarbazine (DTIC) in pregnancy

Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies

Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study

Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia

Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group

Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group

Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).

Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study

Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM

RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent

The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

The transcription factor GLI1 cooperates with the chromatin remodeler SMARCA2 to regulate chromatin accessibility at distal DNA regulatory elements

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide.